MRK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	17.89M
Average Volume	8.57M
Market Cap	317.97B
EPS	$0 ( 2024-05-28 )
Next earnings date	( $2.14 ) 2024-08-06
Last Dividend	$0.770 ( 2024-03-14 )
Next Dividend	$0 ( N/A )
P/E	139.49
ATR14	$0.0760 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-04	Smart Dalton	Buy	612	Common Stock
2024-05-03	Smart Dalton	Buy	1 530	Common Stock
2024-05-04	Smart Dalton	Sell	302	Common Stock
2024-05-03	Smart Dalton	Sell	590	Common Stock
2024-05-03	Smart Dalton	Buy	516	Common Stock

INSIDER POWER
25.95
Last 99 transactions
Buy: 1 325 861 \| Sell: 852 034

Volume Correlation

Long: 0.44 (neutral)

Short: -0.16 (neutral)

Signal:(60.922) Neutral

Merck & Co Inc Correlation

10 Most Positive Correlations
STXM	0.889
KLG	0.877
EFT	0.862
GEV	0.858
HAFN	0.856
MITT-PC	0.849
UTI	0.841
IHTA	0.831
CTRI	0.829
FINS	0.827

10 Most Negative Correlations
YALA	-0.884
BIGZ	-0.874
OAK-PA	-0.861
OAK-PB	-0.858
WRB-PE	-0.851
QVOY	-0.848
XPEV	-0.848
RTO	-0.847
GNE	-0.844
CNMD	-0.843

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Merck & Co Inc Correlation - Currency/Commodity

-0.23
( neutral )

-0.40
( neutral )

0.00
( neutral )

-0.02
( neutral )

-0.23
( neutral )

Merck & Co Inc Financials

Annual	2023
Revenue:	$59.87B
Gross Profit:	$43.89B (73.31 %)
EPS:	$0.140

FY	2023
Revenue:	$59.87B
Gross Profit:	$43.89B (73.31 %)
EPS:	$0.140

FY	2022
Revenue:	$59.28B
Gross Profit:	$41.87B (70.63 %)
EPS:	$5.73

FY	2021
Revenue:	$48.70B
Gross Profit:	$35.08B (72.02 %)
EPS:	$5.16

Financial Reports:

No articles found.

Merck & Co Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.690 (N/A)	$0.730 (N/A)	$0.730 (N/A)	$0.730 (N/A)	$0.730 (N/A)	$0.770 (N/A)	$0.770 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Merck & Co Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.58 - Stable (31.51%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00663	1970-06-02
Last Dividend	$0.770	2024-03-14
Next Dividend	$0	N/A
Payout Date	2024-04-05
Next Payout Date	N/A
# dividends	215	--
Total Paid Out	$53.35	--
Avg. Dividend % Per Year	2.29%	--
Score	6.13	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.58
Div. Directional Score	9.03	--

Next Divdend (Est)
(2024-07-05)

$0.776 Estimate 62.32 %

Dividend Stability

1.00 Excellent

Dividend Score

6.13

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1970	$0.0206	1.40%
1971	$0.0292	2.31%
1972	$0.0224	1.35%
1973	$0.0327	1.36%
1974	$0.0278	1.31%
1975	$0.0371	2.09%
1976	$0.0378	2.04%
1977	$0.0411	2.31%
1978	$0.0465	3.27%
1979	$0.0530	2.94%
1980	$0.0628	3.34%
1981	$0.0702	3.08%
1982	$0.0744	3.28%
1983	$0.0757	3.39%
1984	$0.0809	3.37%
1985	$0.0875	3.54%
1986	$0.106	2.90%
1987	$0.143	2.14%
1988	$0.208	2.38%
1989	$0.274	3.01%
1990	$0.321	2.57%
1991	$0.378	2.66%
1992	$0.458	1.73%
1993	$0.506	2.42%
1994	$0.554	3.29%
1995	$0.610	3.34%
1996	$0.706	2.30%
1997	$0.830	2.18%
1998	$0.946	1.84%
1999	$1.070	1.50%
2000	$1.202	1.86%
2001	$1.316	1.48%
2002	$1.356	2.38%
2003	$4.14	7.45%
2004	$1.432	3.19%
2005	$1.452	4.87%
2006	$1.452	4.65%
2007	$1.452	3.46%
2008	$1.452	2.65%
2009	$1.452	4.91%
2010	$1.452	4.11%
2011	$1.490	4.33%
2012	$1.613	4.41%
2013	$1.650	4.18%
2014	$1.689	3.58%
2015	$1.726	3.16%
2016	$1.765	3.52%
2017	$1.802	3.14%
2018	$1.899	3.54%
2019	$2.16	2.99%
2020	$2.37	2.69%
2021	$2.61	3.38%
2022	$2.80	3.64%
2023	$2.96	2.66%
2024	$0.770	0.68%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend King	2023-06-30	Quarterly	2	5.23%	8.53
ACP	Dividend Royal	2024-05-22	Monthly	14	11.88%	8.50
PVL	Dividend Royal	2023-11-15	Monthly	14	9.37%	8.50
ARR	Dividend Royal	2024-05-14	Monthly	15	11.08%	8.50
ACV	Dividend Royal	2024-06-13	Monthly	10	10.19%	8.50
AVK	Dividend Royal	2024-05-14	Monthly	22	9.54%	8.31
AFG	Dividend Royal	2024-04-12	Bi-Monthly	39	9.39%	8.06
JPT	Dividend King	2023-11-02	Monthly	8	4.19%	8.05
VCIF	Dividend Royal	2023-08-18	Monthly	6	8.05%	8.02
EDI	Dividend Royal	2023-12-07	Monthly	13	8.85%	7.94

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0375	1.500	9.25	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0218	1.200	9.27	10.00	[0 - 0.3]
returnOnEquityTTM	0.0584	1.500	-0.462	-0.693	[0.1 - 1]
payoutRatioTTM	3.27	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.253	0.800	8.74	6.99	[1 - 3]
quickRatioTTM	0.728	0.800	-0.421	-0.337	[0.8 - 2.5]
cashRatioTTM	0.226	1.500	9.86	10.00	[0.2 - 2]
debtRatioTTM	0.323	-1.500	4.61	-6.92	[0 - 0.6]
interestCoverageTTM	5.60	1.000	9.04	9.04	[3 - 30]
operatingCashFlowPerShareTTM	5.83	2.00	8.06	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.36	2.00	7.82	10.00	[0 - 20]
debtEquityRatioTTM	0.848	-1.500	6.61	-9.91	[0 - 2.5]
grossProfitMarginTTM	0.747	1.000	0.889	0.889	[0.2 - 0.8]
operatingProfitMarginTTM	0.110	1.000	9.80	9.80	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.431	1.000	8.72	8.72	[0.2 - 2]
assetTurnoverTTM	0.580	0.800	9.46	7.57	[0.5 - 2]
Total Score				11.48

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	137.90	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0584	2.50	-0.297	-0.693	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.36	2.00	8.55	10.00	[0 - 30]
dividendYielPercentageTTM	2.39	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.83	2.00	8.06	10.00	[0 - 30]
payoutRatioTTM	3.27	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	20.69	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.240	1.000	6.49	0	[0.1 - 0.5]
Total Score				6.58

Merck & Co Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Merck & Co Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.